Meta-analysis of the treatment of chronic obstructive pulmonary disease by tonifying lung and kidney

Objective:To A randomized controlled trial(RCTS)of lung tonifying and kidney tonifying in the treatment of chronic obstructive pulmonary disease(copd)by meta-analysis.Methods:Computer retrieval of databases such as CNKI、VIP、WanFang、Cochrane Library、EMbase、PubMed.The retrieval time was from the database construction to March 2020,and two evaluators were selected to screen the documents according to the na sorting standards,extract the data with Excel 2010 software,and perform Meta analysis with Rev Man5.3 software.Results:21 RCTS were included.Meta-analysis results show that compared with the conventional treatment,the method of supplementing lung and tonifying kidney can obviously improve lung function(MD=1.69,95%CI[1.36,2.01],P<0.00001)、reduce TCM syndrome score(MD=39.83,95%CI[18.10,61.56],P=0.0003)、improve life quality(MD=-5.90,95%CI[-8.95,-2.85],P=0.0001)、regulates serum immunoglobulin(MD=0.37,95%CI[0.31,0.44],P<0.00001)、improve 6MWD(MD=39.83,95%CI[18.10,61.56],P=0.0003)、improve CAT(MD=-1.68,95%CI[-2.05,-1.30],P<0.00001).The differences were statistically significant.For improved T lymphocyte subsets(MD=0.96,95%CI[-0.10,2.03],P=0.08)not statistically significant.Conclusion:Lung-tonifying kidney-tonifying method had better efficacy in improving lung function,reducing TCM syndrome score,improving quality of life,improving immunoglobulin,improving 6WMD,improving CAT,but the efficacy in improving t-lymphocyte subgroup was similar to that in the control group.Due to the limited quantity and quality of samples included in this paper,more multicenter randomized controlled trials with rigorous design of large samples should be carried out for verification.

Stearoyl-CoA desaturase 1 inhibitor supplemented with gemcitabine treatment reduces the viability and fatty acid content of pancreatic cancer cells in vitro

Objective:Pancreatic cancer(PC)is an aggressive cancer with ineffective treatment.Inhibition of stearoyl-CoA desaturase 1(SCD1)suppresses cancer proliferation and might act as a novel chemotherapy supplement,but this has not been investigated in PC.Here,the effects of SCD1 inhibitor CAY10566 supplemented with gemcitabine treatment(gemcitabine+CAY10566)on PC cell viability,apoptosis,phenotype,fatty acid content,platelet-derived growth factor release,and cell size were investigated.Methods:Human PC cell line(PANC-1)was treated with SCD1 inhibitor CAY10566 with or without gemcitabine.Cell viability was assayed using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide and apoptosis and phenotype were determined using flow cytometry.Fatty acid content and platelet-derived growth factor release were measured by enzyme-linked immunosorbent assay.Cell size was determined using scanning electron microscopy.Results:Half-maximal inhibitory concentration of gemcitabine or CAY10566 significantly reduced PANC-1 viability compared to gemcitabine alone(P<0.0001).No significant differences in the phenotype of phosphatidylserine,tissue factor or basigin expression were detected at therapeutic doses(P>0.05).Apoptosis was significantly increased following incubation with CAY10566(P<0.05).Fatty acid content of cells was significantly higher following gemcitabine treatment compared to CAY10566 alone or gemcitabine+CAY10566(P<0.05).Platelet-derived growth factor released by gemcitabine-treated cells was significantly increased compared to 142 nM CAY10566 alone or gemcitabine+CAY10566(P<0.01).CAY10566 did not affect the size of isolated tumor cells but gemcitabine+CAY10566 significantly increased the size compared to the control(P<0.05).Cell viability decreased significantly after the treatment with gemcitabine+CAY10566 compared with CAY10566 alone(P<0.05)and gemcitabine alone(P<0.01).However,when cycles of chemotherapy were mimicked and treatment was removed,the number of cell viability was significantly reduced(P<0.05).Conclusion:This study suggests that CAY10566 may be a suitable supplement for gemcitabine chemotherapy for PC.

新型冠状病毒肺炎患者的清醒俯卧位--这是个时间问题

新型冠状病毒肺炎(COVID-19)患者当出现进行性低氧性呼吸衰竭时,清醒俯卧位可以通过调节呼吸力学来改善患者的临床结局。因为该干预措施操作简单可行,所以很有吸引力,并且已有证据表明,在需要有创机械通气的急性呼吸窘迫综合征的患者中可以获益。然而在COVID-19患者,尤其是不需要机械通气的COVID-19患者中关于应用俯卧位的相关研究数据较少。